Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C16H24N2O · HCl
CAS Number:
Molecular Weight:
296.84
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Ropinirole hydrochloride, powder, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
light yellow
solubility
H2O: >10 mg/mL
originator
GlaxoSmithKline
SMILES string
Cl.CCCN(CCC)CCc1cccc2NC(=O)Cc12
InChI
1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H
InChI key
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Gene Information
human ... DRD2(1813), DRD3(1814), DRD4(1815)
Biochem/physiol Actions
Ropinirole hydrochloride is effectively used to treat early and late Parkinson′s disease.
An agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4. It has negligible effect on D1-receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is said to have virtually no affinity to 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, α1-, α2-, and β-adrenoreceptors. Used as antiparkinsonian drug.
Selective D2 dopamine receptor agonist, antiparkinsonian
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Ropinirole hydrochloride
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Francisco J Zagmutt et al.
The International journal of neuroscience, 122(7), 345-353 (2012-02-07)
The comparative safety profiles of monotherapeutic treatments for Parkinson's disease (PD) can provide valuable therapeutic information. The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole
N Hattori et al.
Journal of clinical pharmacy and therapeutics, 37(5), 571-577 (2012-03-07)
Ropinirole hydrochloride, a dopamine receptor agonist with a non-ergot alkaloid structure, is highly selective for the dopamine D(2) /D(3) receptors. This study was conducted to evaluate the steady-state pharmacokinetics, safety and efficacy after repeated oral administration of prolonged-release tablets of
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Benjamin J Dorfman et al.
Parkinsonism & related disorders, 19(2), 269-270 (2012-07-04)

